| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Nasus Pharma Ltd.$3.3
0 (0%)
D 24Pipeline Score Richly Valued Pharma · Clinical
Market Cap
24.98 M
EPS
-0.19
P/E Ratio
-
Value Trade
52.31 K
0 %
Week
-17.14 %
1 Month
-42 %
3 Month
-61.33 %
6 Month
-63.75 %
5 Year
-63.75 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
35.32 K
52 Week Range
1.98 - 9.99
% held by Insiders
66.83 %
% held by Institutions
25.24 %
Enterprise Value
23.65 M
Total Shares
11.70 M
Short %
2.68 %
Float Shares
6.44 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D24
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal4
Drugs Scored0.1x
rNPV / MCap Top 23%
Micro Cap (rank 698 of 905)
Percentile RankNasus Pharma Ltd. faces pipeline headwinds (24/100), with $134M risk-adjusted pipeline value, led by Epinephrine Product, in Anaphylaxis (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FMXIN002 single dose Small molecule | Anaphylaxis | Phase 1 | NCT07228325 | 7% | $37M | ENROLLING BY_INVITATION | 50 | FAST | D (35) | Apr 1, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NSRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
NSRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NSRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NSRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NSRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
NSRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NSRXNasus Pharma to Participate in the Zacks Life Sciences Investor Forum
Nasus Pharma Ltd. will present at the Zacks Life Sciences Investor Forum on June 24-25, 2026. The virtual event will feature live presentations and interactive Q&A sessions for investors. The company focuses on developing intranasal products, including a needle-free epinephrine alternative for anaphylaxis. A replay of the presentation will be available post-event.
Read more →NSRXNasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Nasus Pharma announced positive results from a preclinical study of NS003, an intranasal formulation of ondansetron. The study demonstrated a pharmacokinetic profile comparable to intravenous ondansetron, with a favorable safety profile. The company plans to initiate a first-in-human PK study in Q3 2026, aiming to address unmet needs in nausea management for chemotherapy patients.
Read more →NSRXNasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
Nasus Pharma will host a virtual KOL event on June 10, 2026, to discuss NS002, its intranasal epinephrine candidate for anaphylaxis. Experts will review Phase 2 data showing NS002's advantages over traditional EpiPen® injections. The event aims to address the unmet needs in anaphylaxis treatment, especially for pediatric patients.
Read more →NSRXNasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Nasus Pharma has reported positive topline results from its Phase 2 study of NS002, indicating its potential as a best-in-class epinephrine delivery system. The company plans to initiate a pivotal study for NS002 in Q4 2026, with a readout expected in Q1 2027. Additionally, Nasus is advancing its pipeline with other intranasal products targeting nausea, metabolic disorders, and cardiovascular diseases, all set for first-in-human studies in 2026.
Read more →NSRXNasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold NS002
Nasus Pharma has announced positive results from a Phase 2 clinical study of NS002, an intranasal epinephrine powder formulation aimed at treating anaphylaxis. The study showed NS002 achieved a significantly faster delivery of epinephrine compared to EpiPen, with 88.4% of subjects reaching the therapeutic threshold at 5 minutes. Additionally, NS002 exhibited a favorable safety profile with no serious adverse events. The company is set to initiate a pivotal clinical study for NS002 in the fourth quarter of 2026, seeking to provide a needle-free alternative for patients experiencing anaphylaxis.
Read more →NSRXNasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
Nasus Pharma announced a conference call on March 16, 2026, to present topline analysis from its Phase 2 clinical study of NS002, an intranasal epinephrine powder. The call will include a data presentation followed by a Q&A session. NS002 is being developed as a needle-free alternative for treating anaphylaxis.
Read more →NSRXNasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Nasus Pharma Ltd. will present at the Life Sciences Investor Forum on March 11, 2026. CEO Dan Teleman will lead the presentation, highlighting the company's focus on intranasal products for emergency medical conditions. The forum will also offer opportunities for one-on-one meetings with management.
Read more →NSRXTHE COMPANIES LAW, 1999 A LIMITED LIABILITY COMPANY AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF Nasus Pharma Ltd. Preliminary 1. Definitions; Interpretation . (a) In these Articles, the following terms (whether or no
The article presents the amended and restated Articles of Association for Nasus Pharma Ltd., a limited liability company governed under the Israeli Companies Law. It defines key terms and establishes the framework for the company's governance, objectives, and capital structure. The Articles outline the rights of shareholders, the powers of directors, and provisions for meetings and resolutions, ensuring compliance with relevant laws and regulations. Overall, the document serves as a comprehensive guide for the company's operational framework.
Read more →NSRXNasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma Ltd. announced its participation in several upcoming investor conferences in February and March. The company, which specializes in developing intranasal products, will have management available for one-on-one meetings. This engagement highlights Nasus Pharma's commitment to investor relations and its innovative approach to addressing acute medical conditions.
Read more →NSRXNasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
Nasus Pharma announced that it will present data on NS002, an investigational intranasal epinephrine powder, at the AAAAI 2026 Annual Meeting. The company emphasizes the product's potential for rapid absorption and stability, positioning it as a novel, needle-free alternative for treating anaphylaxis. The presentation will take place from February 27 to March 2 in Philadelphia.
Read more →NSRXNasus Pharma Announces Closing of $15.0 Million Private Placement
Nasus Pharma has successfully closed a $15 million private placement of ordinary shares and warrants. The funds will be used to advance their NS002 intranasal epinephrine product towards a pivotal study and NDA submission. The financing is expected to enhance the company's balance sheet and support ongoing development activities.
Read more →NSRXNasus Pharma Announces Pricing of $15.0 Million Private Placement
Nasus Pharma Ltd. has announced a private placement of ordinary shares and warrants, raising approximately $15 million. The placement involves both new and existing investors and is expected to close around February 12, 2026. Proceeds will be utilized to advance the clinical development of NS002 and initiate studies for other products in the pipeline.
Read more →NSRXDear Nasus Pharma Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of Nasus Pharma Ltd. (the " Company "), to be held on
Nasus Pharma Ltd. has announced a Special General Meeting for shareholders scheduled for March 5, 2026, to discuss various proposals. Key agenda items include increasing the company's share capital and approving equity-based compensation for executives. Shareholders of record as of February 9, 2026, are entitled to vote either in person or via proxy. The board recommends approval for all proposals, highlighting their confidence in the company's future direction.
Read more →NSRXNasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Nasus Pharma announced positive interim results from its Phase 2 study of NS002, an intranasal epinephrine powder for anaphylaxis. The study showed NS002 achieved faster absorption and higher peak epinephrine levels compared to EpiPen®. The drug was well-tolerated, with no serious adverse events reported. Full results are expected by Q1 2026, with a pivotal study planned for Q4 2026.
Read more →NSRXNASUS PHARMA LTD. CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 UNAUDITED U.S DOLLARS IN THOUSANDS INDEX Unaudited Interim Condensed Balance Sheets F-2 Unaudited Interim Condensed Statements of Operations F-3 Unaudi
Nasus Pharma Ltd. has released its condensed financial statements as of June 30, 2025, which remain unaudited. The document includes interim balance sheets and statements of operations, although it does not provide detailed financial performance metrics. This lack of audited verification and comprehensive data may create uncertainty regarding the company's financial health and operating results.
Read more →NSRXNasus Pharma CEO Issues 2025 Letter to Shareholders
Nasus Pharma's CEO, Dan Teleman, shared a letter highlighting the company's achievements in 2025, including the advancement of NS002, an intranasal epinephrine formulation. The company successfully completed an IPO, raising $10 million, and received Health Canada authorization for a Phase 2 clinical study. Positive trial results indicate NS002's potential for faster epinephrine delivery, crucial for anaphylaxis treatment.
Read more →NSRXNasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer Veteran CFO appointment underscores the Company's commitment to building a strong leadership team as
Nasus Pharma announced the appointment of Eyal Rubin as the new Executive Vice President and Chief Financial Officer. With over two decades of experience in global biotechnology and pharmaceuticals, Rubin is expected to enhance the company's financial operations during a crucial growth phase. The leadership believes his extensive background in capital markets will be invaluable as Nasus Pharma continues advancing its clinical and commercial programs, particularly its innovative intranasal therapeutics.
Read more →NSRXNasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinet
Nasus Pharma Ltd. has announced the initiation of its Phase 2 clinical trial for NS002, an investigational intranasal epinephrine formulation aimed at treating anaphylaxis. The first participant has been dosed in Canada, marking a significant milestone for the company's development program. The trial will compare the bioavailability and pharmacokinetics of NS002 with existing autoinjector options like EpiPen. Interim results from this study are expected in the first quarter of 2026.
Read more →NSRXNasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program Strategic collaboration with leading global manufacturer of drug delivery systems strengthens
Nasus Pharma Ltd. has entered into a significant collaboration with Aptar France S.A.S. to enhance the development and commercialization of its NS002 intranasal epinephrine product. This partnership provides robust manufacturing and technical expertise to support the regulatory submissions required for both the U.S. FDA and the European Medicines Agency. The collaboration aims to streamline the pathway for NS002, a needle-free alternative for patients experiencing anaphylaxis. However, the company's forward-looking statements highlight potential uncertainties regarding the development timeline and regulatory risks.
Read more →NSRXNasus Pharma Announces Closing of Initial Public Offering Tel Aviv, Israel
Nasus Pharma Ltd. has successfully closed its initial public offering, raising $10 million through the sale of 1,250,000 ordinary shares priced at $8.00 each. The company's shares began trading on the NYSE American under the ticker NSRX. The proceeds will primarily fund the development of the intranasal Epinephrine program and cover general corporate expenses. The offering's registration statement was declared effective by the SEC on August 12, 2025.
Read more →Competitive Position
How NSRX ranks across every disease it competes inCompetitive Position is a premium feature
See how NSRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial